(1461072-02) Immune Response During Chronic Critical Illness

Over the past decades, improved sepsis identification and early therapies have decreased short term mortality in sepsis. Consequently, increasing number of patients now present with chronic critical illness (CCI). Emerging evidence implicates, among many pathologies, significant and persistent alterations to the myeloid cell compartment of the septic host. These are associated with poor outcomes and are potentially modifiable to improve patient outcomes in CCI.

Speaker:  Dr. Philip Efron, University of Florida who is supported by NIH for over a decade, studies the role of pathologic myeloid activation, particularly myeloid derived suppressor cells (MDSCs) in pathogenesis of CCI. Dr. Efron will discuss his ongoing studies to describe the role of MDSCs in patients in surgical sepsis.